ライフサイエンスコーパス: HPV DNA Test

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 vulvovaginal specimen collection for Pap and HPV DNA testing.

2 cancer screening with human papillomavirus (HPV) DNA testing.

3 Compared with reflex HPV DNA testing, a strategy of repeat cervical cytology

4 Whether HPV DNA testing alone is useful in primary screening rem

5 usly evaluated with the Digene HC2 high-risk HPV DNA test and found 95.4% concordance between the ass

6 -21 years were seen at 4-month intervals for HPV DNA testing and cytology.

7 screening strategies that incorporate DVI or HPV DNA testing and eliminate colposcopy may offer attra

8 New and sensitive technologies such as HPV DNA testing and liquid-based cytology are more likel

9 Cervical and vulvovaginal samples for HPV DNA testing and Papanicolaou testing were collected

10 tocervical tissue were obtained and used for HPV DNA testing, and liquid-based cytologic testing (Pap

11 eening strategies (VIA, human papillomavirus HPV DNA testing, and Pap cytology) in a periurban commun

12 have been published this year on the use of HPV DNA testing as a primary screening modality and as a

13 enter ASCUS-LSIL Triage Study has shown that HPV DNA testing can be used safely to minimize intervent

14 $381 590 per QALY for combined cytology and HPV DNA testing, depending on age and screening frequenc

15 The sensitivity of HPV DNA testing for HSIL was equivalent to, if not great

16 6 950 to $272 350 per QALY for cytology with HPV DNA testing for triage of equivocal results and from

17 Respondents reported ever using HPV DNA tests for both approved and nonapproved indicati

18 strategies that differ by test (cytology or HPV DNA testing), frequency, and start age versus screen

19 when strategies were compared incrementally, HPV DNA testing generally was more effective but also mo

20 Since 1999, human papillomavirus (HPV) DNA tests have been approved only for abnormal cerv

21 quencing and the Qiagen digene HC2 high-risk HPV DNA test (hc2), demonstrated overall positive agreem

22 d with current screening that uses sensitive HPV DNA testing, HPV vaccination is associated with less

23 ervical cancer worldwide, but the utility of HPV DNA testing in cervical cancer prevention has not be

24 ion using clinician-collected anal swabs for HPV DNA testing obtained during a 1-year prospective stu

25 cation of 5% acetic acid, cervicography, and HPV DNA testing of a clinician-obtained cervical sample.

26 For women with ASCUS Pap tests, HPV DNA testing of residual specimens collected for rout

27 The false-positive rates for HPV DNA testing of self-collected vaginal samples and Pa

28 Human papillomavirus (HPV) DNA testing of women having Papanicolaou (Pap) smea

29 Persistence can be measured by repeated HPV DNA tests or by cytologic testing.

30 To assess HPV DNA testing practices, we mailed surveys to 6906 ran

31 Reflex HPV DNA testing provides the same or greater life expect

32 The next least costly strategy was HPV DNA testing resulting in a reduction in total cancer

33 arance was defined as 2 consecutive negative HPV DNA test results.

34 We compared HPV DNA-testing results from 146 matched exfoliated-cell

35 H13 is a lower-cost HPV DNA test that might be useful for primary screening

36 Interventions are needed to discourage HPV DNA test use for nonapproved indications.

37 Reflex HPV DNA testing uses either residual liquid-based cytolo

38 men without hysterectomies underwent initial HPV DNA testing using the original Hybrid Capture Tube t

39 Awareness (87%) and ever use (67%) of HPV DNA tests was high.

40 bosomal RNA gene amplicon pyrosequencing and HPV DNA testing were conducted annually in serial cervic

41 on Survey and had results of oral and penile HPV DNA testing were examined.

42 were obtained for liquid-based cytology and HPV DNA testing with two first-generation assays (Amplic

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。